BVF Partners L.P. disclosed a 9.99% stake in Entera Bio Ltd.’s ordinary shares. The group filed a Schedule 13D on Aug. 4, 2026 following two private placements in April and July. The move gives BVF direct board influence and signals a hands-on role in Entera Bio’s governance.
Investor Intent
Under the July Securities Purchase Agreement, BVF Partners gained the right to designate two directors to Entera Bio’s board, with one designee expected to sit on the Nominating and Governance Committee. If BVF’s holdings drop below set levels, its board rights scale down to one seat and then terminate, and the affected designees must resign within 30 days of the board’s request.
Entera Bio agreed to work with the BVF designees to add two new independent directors within 18 months, with one current independent director to step down as part of an orderly refresh. BVF and other purchasers also agreed to “vote all shares in favor” of proposals to increase the equity plan and provide executive grants intended to restore pre-transaction ownership levels.
Investor's Background
BVF Partners L.P. is a Delaware limited partnership based in San Francisco that manages investments for Biotechnology Value Fund entities and related accounts. The firm focuses on biotechnology and life sciences, often taking concentrated positions and engaging with management teams. BVF has a track record of active involvement in small- and mid-cap biotech companies to influence strategy and governance.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.